Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC):long-term results of a multicentre, randomised, controlled, phase 3 trial

Autor: Marjorie Tomlinson, Juan W. Valle, Meg Finch-Jones, O. James Garden, S Pugh, Tamas Hickish, Joanne Hornbuckle, Sharadah Essapen, Raaj K. Praseedom, Chan Ton, Marcia Hall, Alison Brewster, Sarah Smith, A Mayer, Nariman Karanjia, Stephen Falk, Nagappan Kumar, Mark A. Hill, Stephen Fenwick, Tim Maughan, John Bridgewater, Alison Brown, Sherif Raouf, Andrea Corkhill, Amy Whitehead, Vanessa Potter, Charlotte Rees, Tom Diamond, Ajith K. Siriwardena, David J. Smith, Susan Cleator, Charles Wilson, Sarah Slater, John N. Primrose, David Cunningham, Gareth Griffiths, Hassan Malik, Nasim Ali, Alex Allen, Christopher Baughan, Satya Bhattacharya, Timothy Iveson, Charles Lowdell, Satvinder Mudan, Brian R. Davidson, Louise Stanton, Paul Ross, Luke Nolan, Iain Cameron, Ann O'Callaghan, Robert J. Thomas, Ewan Brown, Tom Maishman, Anne Moody, Sally Clive, Clare Barlow, Mike Radford, Nua Chan Ton, Georgina Walker, David Tsang, Derek A. O'Reilly, Alaaeldin Shablack, Colin Purcell, Mark Peterson, Zina Eminton, Myrddin Rees, Nigel Heaton, Jane Mellor

Publikováno v: New EPOC investigators 2020, ' Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC) : long-term results of a multicentre, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 398-411 . https://doi.org/10.1016/S1470-2045(19)30798-3
The Lancet. Oncology

Background: The interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction in progression-free survival in patients allocated to cetuximab plus chemotherapy compared with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1626d37868998ab4d8cd96edfc217e80
https://doi.org/10.1016/S1470-2045(19)30798-3